Cellectis Appoints Stéphane Depil as Senior VP of Research & Development
Biopharmaceutical company Cellectis has appointed immuno-oncology expert Stéphane Depil as Senior Vice President of Research & Development and Chief Medical Officer. He will oversee the company's clinical stage development.
French biopharmaceutical company Cellectis announced on December 4, 2017, the appointment of Stéphane Depil, an immuno-oncology specialist, to the position of Senior Vice President of Research & Development and Chief Medical Officer. The company focuses on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART).
In his new role, Depil will be responsible for advancing Cellectis' product candidates into clinical-stage development. He will also manage the strategic and operational aspects of all therapeutic activities and supervise research and development projects. Depil will maintain his academic and research commitments as an adjunct professor at Léon Bérard Cancer Center and University Claude Bernard Lyon 1 in France.
Cellectis is developing cell therapies, particularly for difficult-to-treat cancers. Its technology utilizes gene-edited allogeneic CAR T-cells, known as UCART, which are designed to treat cancer patients.
Stéphane Depil brings extensive experience in preclinical and clinical development, as well as regulatory affairs from previous leadership roles in the pharmaceutical and biotechnology sectors. This appointment underscores Cellectis' commitment to advancing novel cancer treatments.